Answers are grounded in this paper and cite their sources.
Background Cancer immunotherapy faces persistent limitations due to its reliance on single-signal therapeutic architectures, which are vulnerable to antigen loss, off-tumor toxicity, and tumor heterogeneity. A fundamental contributor to therapeutic failure is the generation of biological decision errors — false-positive activation in normal tissues and false-negative missed recognition in antigen-low tumors. Objective We propose the Adaptive Anti-Error Biological System (AABS), a conceptual framework designed to improve therapeutic precision through structured multi-signal validation and conditional effector activation. A simplified implementation, AABS-01, is introduced as a trimodular conditional therapeutic model integrating tumor priming, dual-signal AND-gate logic, and conditional effector engagement. Framework AABS-01 operates through three coordinated layers: (1) a Tumor Priming Layer enhancing antigen visibility through tumor-restricted IFN-γ conditioning, epigenetic modulation, and TME normalization; (2) a Validation Layer implementing Boolean AND-gate logic requiring simultaneous detection of two independent tumor-associated signals; and (3) an Effector Layer triggering localized immune activation exclusively upon validated dual-signal convergence. Bioinformatic support Analysis of TCGA Pan-Cancer Atlas and GTEx v8 transcriptomic data confirms that four candidate signal pairs (HER2/MUC4, EGFR/EpCAM, MSLN/HER2, PD-L1/GD2) achieve corrected Tumor Specificity Index (TSI) values of 18.3x to 46.8x across six cancer types, after correction for inter-signal correlation (r = 0.18–0.44). A revised probabilistic framework accounting for signal co-regulation demonstrates that AND-gate logic achieves 3–8x false-positive rate reduction versus single-signal approaches under empirically observed correlation conditions. Conclusion AABS represents a paradigm shift from reactive to decision-based cancer immunotherapy, grounded in established immunological principles including T-cell multi-signal activation and kinetic proofreading. A five-phase experimental roadmap with quantitative endpoints is provided to guide preclinical and translational validation.
No takes yet. Share an insight, caveat, or question.
Emery M. Kalondero (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: